Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study

详细信息    查看全文

• 作者：Sara Ghaderi ; Nina Gunnes ; Inger Johanne Bakken…
• 关键词：Guillain ; Barré syndrome ; Pandemrix® ; Vaccination ; Influenza ; Registry ; Norway
• 刊名：European Journal of Epidemiology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：31
• 期：1
• 页码：67-72
• 全文大小：493 KB
• 参考文献：1.Guillain-Barré Syndrome Fact Sheet. National Institute of Neurological Disorders and Stroke. http://​www.​ninds.​nih.​gov/​disorders/​gbs/​detail_​gbs.​htm . Accessed 25 October 2014.
  2.van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939–50. doi:10.​1016/​s1474-4422(08)70215-1 .CrossRef PubMed
  3.Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barre Syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case–centered analysis in the vaccine safety Datalink, 2009–2011. PLoS ONE. 2013;8(6):e67185. doi:10.​1371/​journal.​pone.​0067185 .PubMedCentral CrossRef PubMed
  4.Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–23.PubMed
  5.Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461–8. doi:10.​1016/​S0140-6736(12)62189-8 .CrossRef PubMed
  6.Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B. Risk of Guillain-Barre syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf. 2014. doi:10.​1002/​pds.​3638 .
  7.Souayah N, Yacoub HA, Khan HM, et al. Guillain-Barre syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA vaccine adverse event reporting system (2009). Neuroepidemiology. 2012;38(4):227–32. doi:10.​1159/​000336113 .CrossRef PubMed
  8.Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011;29(45):7878–82. doi:10.​1016/​j.​vaccine.​2011.​08.​069 .
  9.Verity C, Stellitano L, Winstone AM, Stowe J, Andrews N, Miller E. Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barre syndrome. Arch Dis Child. 2014;99(6):532–8. doi:10.​1136/​archdischild-2013-304475 .CrossRef PubMed
  10.Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barre syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448–58. doi:10.​1016/​j.​vaccine.​2013.​06.​032 .CrossRef PubMed
  11.Romio S, Weibel D, Dieleman JP, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLoS ONE. 2014;9(1):e82222. doi:10.​1371/​journal.​pone.​0082222 .PubMedCentral CrossRef PubMed
  12.Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10(9):643–51. doi:10.​1016/​S1473-3099(10)70140-7 .CrossRef PubMed
  13.Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149–55. doi:10.​1093/​cid/​ciu005 .CrossRef PubMed
  14.Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case–control study in Europe. BMJ. 2011;343:d3908. doi:10.​1136/​bmj.​d3908 .PubMedCentral CrossRef PubMed
  15.Norsk pasientregister (NPR). The Norwegian Directorate of Health, Oslo, Norway. www.​helsedirektorate​t.​no/​npr . Accessed 02 October 2014.
  16.Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register–SYSVAK. Euro Surveill. 2012;17(16). http://​www.​eurosurveillance​.​org/​ViewArticle.​aspx?​ArticleId=​20147
  17.Norwegian surveillance system for communicable diseases (MSIS). The Norwegian Instiute of Public Health, Oslo, Norway. http://​www.​fhi.​no/​eway/​default.​aspx?​pid=​240&​trg=​Main_​6664&​Main_​6664=​6898:​0:​25,7846:​1:​0:​0:​:​:​0:​0 . Accessed 02 October 2014.
  18.Haberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med. 2013;368(4):333–40. doi:10.​1056/​NEJMoa1207210 .PubMedCentral CrossRef PubMed
  19.Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97. doi:10.​1002/​sim.​2302 .CrossRef PubMed
  20.Crawford NW, Cheng A, Andrews N, et al. Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza a immunisation in Victoria: a self-controlled case series. Med J Aust. 2012;197(10):574–8.CrossRef PubMed
  21.De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308(2):175–81. doi:10.​1001/​jama.​2012.​7342 .PubMed
  22.Vellozzi C, Iqbal S, Stewart B, Tokars J, DeStefano F. Cumulative risk of Guillain-Barre syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. Am J Public Health. 2014;104(4):696–701. doi:10.​2105/​AJPH.​2013.​301651 .CrossRef PubMed
  23.Blasio BF, Iversen BG, Tomba GS. Effect of vaccines and antivirals during the major 2009 A(H1N1) pandemic wave in Norway–and the influence of vaccination timing. PLoS ONE. 2012;7(1):e30018. doi:10.​1371/​journal.​pone.​0030018 .CrossRef PubMed
  
• 作者单位：Sara Ghaderi (1)
  Nina Gunnes (2)
  Inger Johanne Bakken (2)
  Per Magnus (3)
  Lill Trogstad (4)
  Siri Eldevik Håberg (3)
  
  1. Division of Epidemiology, Department of Health Registries, Norwegian Institute of Public Health, Kalfarveien 31, 5018, Bergen, Norway
  2. Division of Epidemiology, Department of Genes and Environment, Norwegian Institute of Public Health, Oslo, Norway
  3. Institute Management and Staff, Norwegian Institute of Public Health, Oslo, Norway
  4. Division of Infectious Disease Control, Department of Vaccines, Norwegian Institute of Public Health, Oslo, Norway
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Epidemiology
  Public Health
  Infectious Diseases
  Cardiology
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7284

文摘

Vaccinations and infections are possible triggers of Guillain-Barré syndrome (GBS). However, studies on GBS after vaccinations during the influenza A(H1N1)pmd09 pandemic in 2009, show inconsistent results. Only few studies have addressed the role of influenza infection. We used information from national health data-bases with information on the total Norwegian population (N = 4,832,211). Cox regression analyses with time-varying covariates and self-controlled case series was applied. The risk of being hospitalized with GBS during the pandemic period, within 42 days after an influenza diagnosis or pandemic vaccination was estimated. There were 490 GBS cases during 2009–2012 of which 410 cases occurred after October 1, 2009 of which 46 new cases occurred during the peak period of the influenza pandemic. An influenza diagnosis was registered for 2.47 % of the population and the vaccination coverage was 39.25 %. The incidence rate ratio of GBS during the pandemic peak relative to other periods was 1.46 [95 % confidence interval (CI) 1.08–1.98]. The adjusted hazard ratio (HR) of GBS within 42 days after a diagnosis of pandemic influenza was 4.89 (95 % CI 1.17–20.36). After pandemic vaccination the adjusted HR was 1.11 (95 % CI 0.51–2.43). Our results indicated that there was a significantly increased risk of GBS during the pandemic season and after pandemic influenza infection. However, vaccination did not increase the risk of GBS. The small number of GBS cases in this study warrants caution in the interpretation of the findings.